PIK3CA and colorectal cancer: Another multicenter phase I/II study of copanlisib with nivolumab is ongoing specifically in relapsed/refractory mismatch-repair proficient advanced colorectal cancer, with early results demonstrating durable responses and meeting the primary endpoint of partial response or complete response in the PIK3CA-mutated cohort (NCT03711058).42